Financials data is unavailable for this security.
View more
Year on year Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd had little change in net income (from 3.97bn to 4.06bn) despite revenues that grew 6.68% from 70.79bn to 75.52bn.
| Gross margin | 17.40% |
|---|---|
| Net profit margin | 5.23% |
| Operating margin | 6.28% |
| Return on assets | 5.29% |
|---|---|
| Return on equity | 10.85% |
| Return on investment | 9.92% |
More ▼
Cash flow in CNYView more
In 2023, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd did not generate a significant amount of cash. However, the company earned 4.10bn from its operations for a Cash Flow Margin of 5.43%. In addition the company used 3.11bn on investing activities and also paid 1.98bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 22.31 |
|---|---|
| Tangible book value per share | 19.82 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.52 |
|---|---|
| Quick ratio | 1.20 |
| Total debt/total equity | 0.4754 |
|---|---|
| Total debt/total capital | 0.3115 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 2.32% and 2.25%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.12% |
|---|---|
| Div growth rate (5 year) | 12.05% |
| Payout ratio (TTM) | 32.10% |
| EPS growth(5 years) | 3.34 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -9.42 |
More ▼
